Cargando…

Comparison in safety of chemotherapy protocols for blood cancers: toxicity of H-CVAD versus GELA/BURKIMAB/PETHEMA LAL

BACKGROUND AND OBJECTIVE: The Hyper-CVAD/Methotrexate-Cytarabine (H-CVAD/MTX-AraC) chemotherapy protocol has been one of the standard treatments for blood cancers, such as Mantle cell lymphoma (MCL), Burkitt’s lymphoma (BL) and B-cell and T-cell acute lymphoblastic leukaemia (ALL). Due to high toxic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marín-Sánchez, Alberto, Martínez-Fernández, Gonzalo, Gómez-Catalán, Irene, Montoya-Morcillo, Mari Carmen, Algarra, Jesús Lorenzo, García, Ángela Ibañez, Hernández-Fernández, Francisco, Romero-Macías, Juan Ramón
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057780/ https://www.ncbi.nlm.nih.gov/pubmed/33912231 http://dx.doi.org/10.3332/ecancer.2021.1206

Ejemplares similares

Policies to clean up toxic industrial contaminated sites of Gela and Priolo: a cost-benefit analysis
por: Guerriero, Carla, et al.
Publicado: (2011)

Visite au LAL
por: Godot, J C, et al.
Publicado: (1994)

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry
por: Martínez, Pilar, et al.
Publicado: (2020)

RAVINDER LAL KAPUR (1938–2006)
por: Bhide, Ajit V.
Publicado: (2006)

Accelerator R and D at LAL-Orsay
por: Le Duff, J
Publicado: (1987)

The Late Rai Bahadur Hira Lal
Publicado: (1924)

Possible cross-feeding pathway of facultative methylotroph Methyloceanibacter caenitepidi Gela4 on methanotroph Methylocaldum marinum S8
por: Takeuchi, Mio, et al.
Publicado: (2019)

Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
por: Sargas, Claudia, et al.
Publicado: (2020)

P1147: FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL
por: Maria Ribera, Josep, et al.
Publicado: (2023)

Beyond Hyper-CVAD in ALL: Highlights From SOHO 2021
Publicado: (2022)

Correction: Possible cross-feeding pathway of facultative methylotroph Methyloceanibacter caenitepidi Gela4 on methanotroph Methylocaldum marinum S8
por: Takeuchi, Mio, et al.
Publicado: (2021)

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
por: Sargas, Claudia, et al.
Publicado: (2023)

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
por: Labrador, Jorge, et al.
Publicado: (2022)

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
por: Martínez-Cuadrón, David, et al.
Publicado: (2022)

Ravinder Lal Kapur, M.D. (1938–2006)
por: Crowther, Lord, et al.
Publicado: (2007)

Ravinder Lal Kapur, M.D. 1938-2006
por: Bhide, Ajit V
Publicado: (2007)

The Special Issue in Honor of Anirudh Lal Nagar: An Introduction
por: Bao, Yong, et al.
Publicado: (2021)

The feasibility of PETHEMA ALL-96 regimen on treatment of patients with acute lymphoid leukemia
por: Ashrafi, Farzaneh, et al.
Publicado: (2023)

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
por: Ayala, Rosa, et al.
Publicado: (2021)

Retinal and Preretinal Hemorrhages in a Patient Receiving Hyper-CVAD Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
por: Peddada, Krishi, et al.
Publicado: (2018)

Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
por: Sargas, Claudia, et al.
Publicado: (2023)

Effectiveness of modified hyper‐CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience
por: Jalaeikhoo, Hasan, et al.
Publicado: (2018)

The Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia: Experience of the Pethema Group and Review of the Literature
por: Montesinos, Pau, et al.
Publicado: (2011)

Mesure lente du profil transversal: - Test au lal -
por: Battisti, S, et al.
Publicado: (1984)

Talks given at the closing session of the LAL/CERN collaboration on LPI
por: Hubner, K, et al.
Publicado: (1987)

The Late Dr. Mohendra Lal Sircar, C.L.E.
Publicado: (1904)

Impact of (intestinal) LAL deficiency on lipid metabolism and macrophage infiltration
por: Bianco, Valentina, et al.
Publicado: (2023)

P498: INCIDENCE, RISK FACTORS AND OUTCOMES OF SECOND NEOPLASMS IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: THE PETHEMA-PALG EXPERIENCE.
por: Sobas, Marta, et al.
Publicado: (2023)

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
por: Labrador, Jorge, et al.
Publicado: (2022)

A kinetic assay of total lipase activity for detecting lysosomal acid lipase deficiency (LAL‐D) and the molecular characterization of 18 LAL‐D patients from Russia
por: Mayanskiy, Nikolay, et al.
Publicado: (2019)

PLZF-RAR(α), NPM1-RAR(α), and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review
por: Sobas, Marta, et al.
Publicado: (2020)

Des coudes supra élargissent l'horizon de l'ALS
Publicado: (2002)

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
por: Martínez-Cuadrón, David, et al.
Publicado: (2022)

Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
por: Ayala, Rosa, et al.
Publicado: (2022)

Hyper-CVAD-Based Stem Cell Microtransplant as Post-Remission Therapy in Acute Lymphoblastic Leukemia
por: Cai, Bo, et al.
Publicado: (2022)

Deepak Lal: Climate change - sun & the stars vs C02-1
Publicado: (2007)

First electron beams from the LEP injector Linacs CERN/LAL collaboration
por: Warner, D J
Publicado: (1986)

Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen
por: Ryu, Il Hwan, et al.
Publicado: (2015)

Complete remission with romidepsin in a patient with T‐cell acute lymphoblastic leukemia refractory to induction hyper‐CVAD
por: Brunvand, Mark W., et al.
Publicado: (2017)

RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
por: Sakhdari, Ali, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a1tio5tqbhoitng2ki1cons6gl